- Global Pharma News & Resources

Tuberculosis Treatment Drugs to Record Remarkable Growth, Projected to Reach $3.2 Billion by 2031

Tuberculosis (TB) is a bacterial infection caused by Mycobacterium tuberculosis. The treatment of TB involves a combination of drugs, known as antituberculosis medications, which are used to effectively kill the bacteria and prevent the development of drug-resistant strains. The standard treatment for active TB consists of a regimen called Directly Observed Therapy Short-course (DOTS), which typically lasts for six to nine months. The global tuberculosis treatment drugs market size was valued at $1.9 billion in 2021, and is projected to reach $3.2 billion by 2031, growing at a CAGR of 5.3% from 2022 to 2031.

HIV Drugs Market in Short:

CAGR: 5.3%
Current Market Size: USD 3.2 Billion
Largest Market: North America
Projection Time: 2022-2031
Base Year: 2022

Download Free Sample Updated PDF: (Including Full TOC, Table & Figures) –

Q1. What are tuberculosis treatment drugs?

A. Tuberculosis treatment drugs such as Isoniazid, Rifampin, Ethambutol, Pyrazinamide and others are used to treat the infection caused by Mycobacterium tuberculosis in lungs.

Q2. What are the key trends in the tuberculosis treatment drugs market report?

A. The major factor that fuels the growth of the tuberculosis tretament drugs market are rise in drug resistant -TB cases, rise in government initiatives to eleminate TB and rise in research activities related to anti-tuberculosis medications.

Value Propositions Related to The Report:

  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

Inquire Your Every Doubt Here:

The DOTS regimen includes several key drugs, such as isoniazid, rifampin, pyrazinamide, and ethambutol. Isoniazid and rifampin are considered the backbone of TB treatment, as they are highly effective in killing the bacteria. Pyrazinamide is particularly effective against dormant bacteria, and ethambutol helps prevent the development of drug resistance. These drugs are usually administered in combination to prevent the bacteria from becoming resistant to any one drug.

In cases of drug-resistant TB, more specialized medications may be required, such as fluoroquinolones, injectable drugs like amikacin or kanamycin, and newer agents like bedaquiline or delamanid. These drugs are used in combination and are often prescribed for a longer duration to effectively treat drug-resistant strains of TB. Adherence to the prescribed treatment regimen is crucial to achieving a cure and preventing the spread of drug-resistant TB. Close monitoring and follow-up by healthcare professionals are essential to ensure treatment success and minimize adverse effects.

Major Key Market Players in the Industry –

  • Lupin,
  • Sanofi,
  • Pfizer Inc.,
  • KGaA (Fresenius Kabi),
  • Johnson & Johnson,
  • Novartis AG,
  • Macleods Pharmaceuticals Ltd.,
  • ANI Pharmaceuticals, Inc.,
  • Otsuka Pharmaceutical Co., Ltd.,
  • Teva Pharmaceutical Industries Ltd.

Market: By Region Outlook

  • North America (U.S., Canada, Mexico)
  • Europe (UK, Germany, France, Spain, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA (Brazil, South Africa, Turkey, Saudi Arabia, Rest of LAMEA)

Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @

Important Questions Being Answered by This Market Report Are –

Q1. Which is the most influencing segment growing in the tuberculosis treatment drugs market report?

Q2. Which are the top companies hold the market share in tuberculosis treatment drugs market?

Q3. Which is base year calculated in the tuberculosis treatment drugs market report?

Q4. What is the market value of tuberculosis treatment drugs market in 2031?

Key findings of the study –

  • On the basis of disease type, the active tuberculosis segment dominated the Tuberculosis treatment drugs industry in terms of revenue in 2021.
  • On the basis of therapy type, first-line therapy segment dominated the market in terms of revenue in 2021.
  • On the basis of distribution channel, the Drug Stores and Retail Pharmacies segment dominated the market in terms of revenue in 2021. However, the online providers segment is anticipated to grow at the highest CAGR during the forecast period.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.


David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975

Editor Details

  • Company:
    • The Wire Times
Last Updated: 25-May-2023